All terms
    Investment & FinanceStartup LifecycleSAFE

    Simple Agreement for Future Equity

    Convertible instrument that converts to equity at a future priced round.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    A SAFE is a financing contract created by Y Combinator in 2013 that gives investors the right to receive shares in a future priced equity round, typically at a discount and/or subject to a valuation cap. Unlike convertible notes, SAFEs carry no interest rate and no maturity date. Since 2018 the standard YC SAFE is post-money, which makes the holder's ownership easier to calculate before the priced round. A SAFE converts when a priced equity round occurs, and has specific terms for a sale or dissolution before conversion. Stacking many SAFEs can produce surprising dilution, so founders should model conversion in the cap table.
    What the regulation says
    SAFEs are securities under U.S. federal law and must be issued under an exemption (typically Reg D 506(b) or 506(c)). Form D filings and state blue-sky notices apply.

    What this means in practice

    Early-stage MedTech companies often raise seed capital through SAFEs to defer the valuation discussion until clinical or regulatory milestones (first-in-human, 510(k) submission, CE mark) materially de-risk the company. Stacking many SAFEs without modeling dilution at conversion is a frequent founder mistake.

    Examples

    • A diagnostics startup raises $2M on a post-money SAFE with a $15M cap to fund an analytical validation study.
    • An implant company uses a discount-only SAFE for a strategic angel before its Series A.
    Common pitfalls
    • •Confusing pre-money and post-money SAFEs - post-money SAFEs guarantee the investor's ownership percentage and are far more dilutive at conversion.
    • •Issuing too many SAFEs with different caps, creating a 'SAFE stack' that surprises founders at the priced round.

    Frequently asked questions

    A pre-money SAFE calculates the investor's conversion price based on the company's valuation before other SAFEs and the new round's investment are added, meaning multiple SAFEs and option pool changes can dilute the investor's eventual ownership in ways that are hard to predict until conversion. A post-money SAFE fixes the investor's ownership percentage at conversion regardless of how much additional SAFE capital is raised afterward, which protects the investor but is significantly more dilutive to founders since each new post-money SAFE stacks on top of prior ones. MedTech founders raising multiple bridge rounds toward a regulatory milestone should model both structures before choosing, since the choice compounds across several capital raises before an eventual priced round.
    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Ecosystems (1)

    Latest in MedTech

    Sources

    3 sources

    Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 2
    Link health: 3 verified· last checked 2026-06-20
    Y Combinator·1SEC·1NVCA·1
    1. 1
      Y Combinator SAFE
      Tier 4 Verified
      Y Combinatorycombinator.com
    2. 2
      SEC Investor Bulletin: SAFEs
      Tier 2 Verified
      SECsec.gov
    3. 3
      NVCA Model Documents
      Tier 4 Verified
      NVCAnvca.org

    Inline markers like [1] jump to the matching reference above.